Condition: Treatment Resistant Depression · MDD · Major Depressive Disorder · Sponsor: University of Texas at Austin
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
This description comes directly from the study's public registry record.
Lauren K Enten, B.S.A. · 512-495-5856 · psychedelics@utexas.edu
Gregory A Fonzo, Ph.D. · fonzolab@austin.utexas.edu
Always discuss trial participation with your own doctor first.
| Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06132178